2023-09-142023-09-142014-01-18Cander, S. vd. (2014). "Comparison of efficacy and safety of once- versus twice-daily insulin detemir added on to oral antidiabetics in insulin-naive type 2 diabetes patients: 24-Week, crossover, treat to target trial in a single center". Primary Care Diabetes, 8(3), 256-264.1751-99181878-0210https://doi.org/10.1016/j.pcd.2014.01.010https://www.sciencedirect.com/science/article/pii/S1751991814000114http://hdl.handle.net/11452/33853Aim: To compare once- versus twice-daily insulin detemir added on OADS therapy in insulin-naive type 2 diabetes patients in terms of efficacy and safety. Methods: An open-label study performed at a single center, comprised a randomized, crossover 24 week with insulin-naive type 2 diabetes patients. Insulin detemir was initiated with mean 0.12 U/kg in all patients (Group I once-daily, Group II twice-daily) and titrated for 24 week. Results: A total of 50 patients completed the study (Group I n:25, Group II n:25). With use of once- and twice-daily insulin, HbA1c values were decreased by 1.8% (+/- 2.0) and 1.5% (+/- 1.4) within the first 12 weeks (p<0.01), whereas increased by 0.21% (+/- 0.7) and 0.14% (+/- 0.8) in the second 12 weeks (p>0.05). The increases in the insulin doses were found as 0.22 U/kg and 0.35 U/kg with once- and twice-daily insulin use, respectively (p:0.04). Although minor hypoglycemic events were similar in both groups in the first 12 weeks, 2-fold increase was found in the patients shifting from once- to twice-daily dose. Within the first and second periods, the body weight of the patients was observed an increase of 0.4 and 1.6 kg with once-daily dose, whereas a decrease of 0.1 and 2.1 kg in the twice-daily dose, in the same period. Conclusion: Once-daily use of insulin detemir up to 0.4 U/kg was found to have similar efficacy and safety as twice-daily use. Twice dose use of insulin did not provide a prominent glycemic control advantage on 1.5-fold higher use of insulin.eninfo:eu-repo/semantics/closedAccessDetemirType 2 diabetesHbA1cOnce dailyHypoglycemiaInsulin doseImproves glycemic controlVariabilityNph insulinAnalogWeight-gainTherapyDouble-blindHypoglycemiaGlarginePredictive(tm)Endocrinology & metabolismGeneral & internal medicineAdministration, oralBiological markersBlood glucoseCross-over studiesDiabetes mellitus, type 2Drug administration scheduleDrug therapy, combinationFemaleHemoglobin a, glycosylatedHumansHypoglycemiaHypoglycemic agentsInjectionsInsulin, long-actingMaleMiddle agedTime factorsTreatment outcomeTurkeyWeight gainArticle0003422557000112-s2.0-849083561932562648324522170Endocrinology & metabolismPrimary health careInsulin Glargine; Insulin Replacement Therapy; Non Insulin Dependent Diabetes MellitusAdultArticleClinical articleControlled studyCrossover procedureDiabetic patientDosage schedule comparisonDrug dose increaseDrug dose titrationDrug efficacyDrug safetyFemaleGlycemic controlHumanInsulin hypoglycemiaMaleNon insulin dependent diabetes mellitusPriority journalRandomized controlled trialTreatment durationWeight gainBloodChemically inducedComparative studyDiabetes mellitus, type 2Drug administrationDrug combinationDrug effectsGlucose blood levelHypoglycemiaInjectionMetabolismMiddle agedOral drug administrationTimeTreatment outcomeTurkeyHemoglobin a1cInsulin detemirOral antidiabetic agentAntidiabetic agentBiological markerGlucose blood levelGlycosylated hemoglobinHemoglobin a1c protein, humanInsulin detemirLong acting insulin